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Abstract
Background: Polo-like kinase 1 (Plk1) is a serine/threonine protein kinase that has been implicated in the
regulation of mitosis. In addition, the activation of mitogen-activated protein kinase (MAPK) is a key event in the
early stage of the growth factor response. The role of Plk1 in MAPK phosphorylation in cells has not been
investigated.
Methods: Immunoblot analysis was used to evaluate Plk1 and MAPK phosphorylation in cells upon stimulation
with platelet-derived growth factor (PDGF). We also generated stable Plk1 knockdown (KD) cells to assess the role
of Plk1 in MAPK activation and cell proliferation. Furthermore, we used a non-phosphorylatable Plk1 mutant to
determine the function of Plk1 phosphorylation in these processes.
Results: Treatment with PDGF increased Plk1 phosphorylation at Thr-210 (an indication of Plk1 activation) in human
airway smooth muscle cells. Plk1 KD attenuated the PDGF-induced phosphorylation of MEK1/2 and ERK1/2 as well as
cell proliferation. However, phosphorylation of Raf-1 and AKT upon stimulation with PDGF was not reduced in Plk1 KD
cells. Furthermore, the expression of T210A Plk1 (alanine substitution at Thr-210) inhibited the PDGF-stimulated MEK1/2
phosphorylation, ERK1/2 phosphorylation and cell proliferation.
Conclusions: Together, these findings suggest that Plk1 is activated upon growth factor stimulation, which may
control the activation of MEK1/2 and ERK1/2, and smooth muscle cell proliferation.
Introduction
Airway smooth muscle cell proliferation contributes to
the pathogenesis of airway remodeling, a key characteris-
tic of chronic asthma [1]. However, the mechanisms that
regulate smooth muscle cell proliferation are not fully
understood.
Polo-like kinase 1 (Plk1) is a serine/threonine protein
kinase that has been implicated in cell-cycle-associated
processes such as centrosome maturation, mitotic spin-
dle assembly, sister chromatid cohesion and cytokinesis
[2, 3]. Knockdown (KD) or depletion of Plk1 induces
mitotic arrest in various nonmuscle cell types [2, 4, 5].
During mitosis and cytokinesis, the functions of Plk1
are regulated by its expression, spatial localization, and
activation [2, 5].
The activation of Plk1 is largely regulated by phos-
phorylation at Thr-210 located in the catalytic domain
of the kinase [2, 6]. In vitro biochemical studies suggest
that phosphorylation at Thr-210 increases Plk1 activity
[6, 7]. In addition, Plk1 is first activated in G2 and
reaches maximal activity in mitosis, coincident with the
kinetics of Thr-210 phosphorylation [4]. By phosphoryl-
ating distinctive substrates, activated Plk1 regulates
centrosomal maturation, spindle organization and cyto-
kinesis [2, 3].
The mitogen-activated protein kinase (MAPK) path-
way plays an essential role in regulating various cellular
functions including cell proliferation [8–10]. In response
to stimulation with growth factors within minutes,
MEK1/2 (MAPK kinase) gets phosphorylated by Raf-1
[10, 11], which in turn phosphorylates and activates
ERK1/2. Activated ERK1/2 phosphorylates several pro-
tein kinases, transcription factors, and other proteins to
promote cell proliferation eventually [8–11].
In addition to mitosis and cytokinesis, Plk1 has been
implicated in the DNA damage response, development
[3], cancer cell invasion [12], apoptosis and autophagy
[13]. However, the role of Plk1 in the early stage of the
growth factor response has not been investigated.
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Here, we find that stimulation with platelet-derived
growth factor (PDGF) induces Plk1 phosphorylation at
Thr-210. KD of Plk1 inhibits the PDGF-induced phos-
phorylation of MEK1/2, ERK1/2 and smooth muscle cell
proliferation. Furthermore, phosphorylation at Thr-210
is required for the Plk1-mediated activation of MEK1/2
and ERK1/2. Thus, we propose that Plk1 is a critical
molecule that regulates the activation of MEK1/2 in




Human airway smooth muscle (HASM) cells were
prepared from human bronchi and adjacent tracheas
obtained from the International Institute for Advanced
Medicine [8, 14–16]. Human tissues were non-
transplantable and consented for research. This study
was approved by the Albany Medical College Commit-
tee on Research Involving Human Subjects. Briefly,
muscle tissues were incubated for 20 min with dissoci-
ation solution [130 mM NaCl, 5 mM KCl, 1.0 mM
CaCl2, 1.0 mM MgCl2, 10 mM Hepes, 0.25 mM EDTA,
10 mM D-glucose, 10 mM taurine, pH 7, 4.5 mg colla-
genase (type I), 10 mg papain (type IV), 1 mg/ml BSA
and 1 mM dithiothreitol]. All enzymes were purchased
from Sigma-Aldrich. The tissues were then washed with
Hepes-buffered saline solution (composition in mM: 10
Hepes, 130 NaCl, 5 KCl, 10 glucose, 1 CaCl2, 1 MgCl2,
0.25 EDTA, 10 taurine, pH 7). The cell suspension was
mixed with Ham’s F12 medium supplemented with 10 %
(v/v) fetal bovine serum (FBS) and antibiotics (100 units/ml
penicillin, 100 μg/ml streptomycin). Cells were cultured at
37 °C in the presence of 5 % CO2 in the same medium. The
medium was changed every 3–4 days until cells reached
confluence, and confluent cells were passaged with trypsin/
EDTA solution [8, 17, 18]. HASM cells (passage 3–10)
from four non-asthmatic donors were used for experi-
ments. They were serum starved for 24 h before treatment
with PDGF.
Immunoblot analysis
Cells were lysed with RIPA 150 (50 mM Tris–HCl,
pH7.6, 150 mM NaCl, 2 mM sodium pyrophosphoate,
0.5 % sodium dexoycholate,1 % NP-40, 0.1 % SDS,
5 mM EDTA) with protease and phosphatase inhibitors
(1 mM benzamidine, 1 mM PMSF, 1 μg/ml aprotinin,
1 μg/ml leupeptin, 1 μg/ml pepstatin, 2 mM sodium
orthovanadate, 5 mM sodium fluoride). Cell lysates were
mixed with SDS sample buffer composed of 1.5 %
dithiothreitol, 2 % SDS, 80 mM Tris–HCl (pH 6.8), 10 %
glycerol and 0.01 % bromophenol blue, and were boiled
for 5 min and separated by SDS-PAGE. Proteins were
transferred to a nitrocellulose membrane. The membrane
was blocked with bovine serum albumin or milk for 1 h
and probed with use of primary antibody followed by
horseradish peroxidase-conjugated secondary antibody
(Thermo Fisher Scientific). Proteins were visualized by
enhanced chemiluminescence (Thermo Fisher Scientific)
using the LAS-4000 Fuji Image System. Antibodies used
were anti-phospho-Plk1 (Abcam), anti-Plk1 (EMD Milli-
pore), anti-phospho-MEK1/2 (Santa Cruz Biotech.), anti-
MEK1/2 (Santa Cruz Biotech.), anti-phospho-ERK1/2 (Cell
signaling), anti-ERK1/2 (Cell signaling), anti-phospho-Raf-
1 (Santa Cruz Biotech.), anti-Raf-1 (Santa Cruz Biotech.)
and anti-GAPDH (Ambion). The levels of total protein or
phosphoprotein were quantified by scanning densitometry
of immunoblots (Fuji Multigauge Software). The lumines-
cent signals from all immunoblots were within the linear
range [14, 19–21].
Assessment of cell proliferation
Cells were seeded in 24-well plates with the F12 medium
with 10 % FBS for at least 18 h. Cells were then serum
starved for 24 h. They were subsequently treated with
PDGF-BB (20 ng/ml) in the medium containing 0.25 %
FBS. Numbers of viable cells were counted using the try-
pan blue exclusion test [9]. Briefly, cell suspension was
incubated with 0.4 % trypan blue for 5 min at room
temperature. Unstained cells (viable cells) were then
counted.
The BrdU (5′-bromo-2′-deoxyuridine) cell prolifera-
tion assay kit (Millipore) was also used to evaluate
DNA synthesis. BrdU is an analog of thymidine, which
is able to incorporate into newly-synthesized DNA.
Cells in 96-well (1.2x 104 cells/well) were treated with
BrdU for 24 hrs. They were then fixed and reacted with
BrdU antibody for 1 h, followed by incubation with sec-
ondary antibody conjugated with peroxidase. They were
reacted with peroxidase substrates, and the reaction
was detected using a Promega GloMax-Multi Micro-
plate reader.
Generation of stable Plk1 KD cells
We used lentivirus-mediated shRNA [14–16, 20] to gen-
erate stable Plk1 knockdown (KD) cells. Briefly, lentiviral
particles encoding Plk1 shRNA (sc-36277-V) or control
shRNA (sc-108080) were purchased from Santa Cruz
Biotechnology. HASM cells were infected with control
shRNA lentiviruses or Plk1 shRNA lentiviruses for 12 h.
They were then cultured for 3–4 days. Positive clones
expressing shRNAs were selected by puromycin. Immu-
noblot analysis was used to determine the protein levels
of Plk1 in these cells. Plk1 KD cells and cells expressing
control shRNA were stable at least five passages after
initial infection.
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In vitro kinase assay
Active Plk1 (40 ng, Millipore) and 2 μg MEK1 (unactive,
Millipore) were placed in 20 μl kinase buffer containing
20 mM HEPES (pH7.5), 60 mM NaCl, 2 mM MgCl2,
5 mM EGTA and 100 μM ATP. Kinase reaction mix was
incubated at 30 °C for 30 min, and stopped by the
addition of the SDS sample buffer [18, 22]. The samples
were boiled for 5 min and separated by SDS-PAGE
followed by membrane transfer. The membrane was
probed with phospho-MEK1/2 antibody, stripped, and
reprobed with MEK1/2 antibody.
Mutagenesis, plasmid purification and cell transfection
T210A Plk1 (alanine substitution at Thr-210) was gener-
ated by using the Quick change II XL site-directed mu-
tagenesis kit (Agilent Technologies). The template
plasmid pcDNA3 3xFlag-Plk1 was kindly provided by
Dr. David Stern (Yale University). The primers were de-
signed using the online service PrimerX (http://
www.bioinformatics.org/primerx/index.htm) and were
synthesized by Invitrogen. The 5′ primer was 5′ –
GGGGAGAGGAAGAAGGCCCTGTGTGGGACTC- 3′.
The 3′ primer was 5′- GAGTCCCACA-
CAGGGCCTTCTTCCTCTCCCC- 3′. The PCR product
was digested with Dpn I at 37 °C for 2-3 h to remove
the parental DNA, and was transformed into XL10-
Gold Ultracompetenet cells (Agilent Technologies).
Plasmids were purified by using the Pureklink Quick
Plasmid Miniprep kit (Invitrogen). DNA sequencing was
performed by Genewiz Life Sciences.
Statistical analysis
All statistical analysis was performed using Prism 6 soft-
ware (GraphPad Software, San Diego, CA). Comparison
among multiple groups was performed by one-way analysis
of variance followed by Tukey’s multiple comparison test.
Differences between pairs of groups were analyzed by
Student-Newman-Keuls test or Dunn’s method. Values of n
refer to the number of experiments used to obtain each
value. P < 0.05 was considered to be significant.
Results
PDGF stimulation induces phosphorylation of Plk1, MEK1/
2 and ERK1/2 in smooth muscle cells
As described earlier, Plk1 has been implicated in mitosis
and cytokinesis in nonmuscle cells [2, 4, 5]. The role of
Plk1 in the early phase of the cellular responses to
growth factor stimulation is largely unknown. We evalu-
ated the effects of PDGF stimulation on Plk1 phosphor-
ylation at Thr-210 (an indication of Plk1 activation) [6].
Human airway smooth muscle cells were serum starved
for 24 h, which synchronizes the cells in G0-G1 [9, 20].
Cells were then stimulated with 20 ng/ml for different
time periods, or left unstimulated. Plk1 phosphorylation
at Thr-210 in the cells was assessed by immunoblot
analysis. In unstimulated cells, the level of Plk1 phos-
phorylation at Thr-210 was relatively low. Stimulation
with PDGF increased Plk1 phosphorylation, which was
evident as early as 2 min after PDGF stimulation, and
persisted for the 40-min duration of the stimulation
(Fig. 1a).
Because the MAPK pathway has been implicated in
growth factor-mediated signaling [8–10], we also deter-
mined the phosphorylation of MEK1/2 and ERK1/2 in
smooth muscle cells. The phosphorylation of MEK1/2
and ERK1/2 was significantly increased 5 min after
PDGF stimulation and maintained 40 min after the
stimulation with PDGF (Fig. 1b and c).
KD of Plk1 attenuates the phosphorylation of MEK1/2 and
ERK1/2 upon PDGF stimulation
To reveal the functional role of Plk1 in the growth
factor-associated process, we evaluated the effects of
Plk1 KD on MEK/1/2 and ERK1/2 phosphorylation in
smooth muscle cells. Stable Plk1 KD cells were gener-
ated by using lentivirus-mediated shRNA. Immunoblot
analysis showed that the protein level of Plk1 in cells in-
fected with viruses for Plk1 shRNA was lower compared
to control cells. However, the protein level of GAPDH
was similar in these cells. Ratios of Plk1/GAPDH were
lower in Plk1 KD cells than in control cells (Fig. 2a).
Plk1 KD cells and cells expressing control shRNA
were stimulated with 20 ng/ml PDGF for 10 min or left
unstimulated. The phosphorylation of MEK1/2 and
ERK1/2 in the cells was determined by immunoblot ana-
lysis. In smooth muscle cells expressing control shRNA,
the phosphorylation of MEK1/2 and ERK1/2 was in-
creased in response to stimulation with PDGF. However,
the PDGF-induced phosphorylation of MEK1/2 and
ERK1/2 was reduced in Plk1 KD smooth muscle cells
(Fig. 2b and c). Basal phosphorylation of MEK1/2 and
ERK1/2 was not affected by Plk1 knockdown.
Raf-1 phosphorylation is not reduced in Plk1 KD cells
Because Raf-1 is known to regulate MEK1/2 phosphoryl-
ation, we also evaluated the effects of Plk1 KD on Raf-1
phosphorylation in smooth muscle cells. Blots of cells
treated with 20 ng/ml PDGF for 10 min were probed
with antibodies against phospho-Raf-1 and total Raf-1.
Raf-1 phosphorylation upon PDGF stimulation was simi-
lar in cells expressing control shRNA and Plk1 KD cells
(Fig. 2d). Basal Raf-1 phosphorylation was also compar-
able in cells expressing control shRNA and Plk1 KD
cells.
Plk1 catalyzes MEK phosphorylation in Vitro
As described above, KD of Plk1 mediates the phosphor-
ylation of MEK1/2 and ERK1/2 without affecting Raf-1
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phosphorylation. Because ERK1/2 is phosphorylated by
the dual-specificity protein kinase MEK1/2, and Plk1 is
not a dual-specificity protein kinase [8, 10], it is unlikely
that Plk1 catalyzes ERK1/2 directly. To verify whether
Plk1 directly mediates MEK phosphorylation, purified
active Plk1 was added to purified unactive MEK1 in kin-
ase buffer. MEK phosphorylation was determined by im-
munoblot analysis. The addition of Plk1 to the kinase
buffer containing MEK1 increased the phosphorylation
of MEK (Fig. 3). The results suggest that Plk1 directly
catalyzes MEK phosphorylation.
KD of Plk1 inhibits smooth muscle cell proliferation
We assessed the effects of Plk1 KD on cell proliferation.
Smooth muscle cells were treated with PDGF for 24–
72 h. The numbers of smooth muscle cells were then
evaluated. Compared to cells expressing control shRNA,
the numbers of Plk1 KD cells were reduced (Fig. 4a).
We also used the BrdU incorporation assay to assess
the effects of Plk1 on DNA synthesis. Basal BrdU in-
corporation was not different between cells expressing
control shRNA and Plk1 KD cells. However, BrdU in-
corporated into newly synthesized DNA was lower in
Plk1 KD cells than in cells expressing control shRNA
(Fig. 4b).
Plk1 silencing does not affect AKT phosphorylation in
smooth muscle cells
In addition to MEK1/2 and ERK1/2 activation, exposure
to growth factors also activates AKT/PKB in smooth
muscle cells [9, 23]. To determine whether AKT activa-
tion is regulated by Plk1, we assessed the effects of Plk1
KD on AKT phosphorylation in cells. Stimulation with
PDGF induced a significant increase in AKT phosphor-
ylation in cells expressing control shRNA and Plk1-
deficient cells (Fig. 5). The average increase in AKT
phosphorylation in these cells was not significantly dif-
ferent 10 min after PDGF stimulation.
The expression of mutant T210A Plk1 inhibits the PDGF-
induced phosphorylation of MEK1/2 and ERK1/2, and cell
proliferation
As described earlier, PDGF stimulation induces Plk1 phos-
phorylation at Thr-210 (Fig. 1a). To determine the role of
Fig. 1 Stimulation with PDGF induces the phosphorylation of Plk1,
MEK1/2 and ERK1/2 in smooth muscle cells. Human airway smooth
muscle (HASM) cells were stimulated with 20 ng/ml PDGF for
different durations or left unstimulated. The phosphorylation of Plk1
(a), MEK1/2 (b) and ERK1/2 (c) in these cells was evaluated by
immunoblot analysis. The phosphorylation levels of the proteins in
stimulated cells were normalized to corresponding unstimulated
cells. * Significantly higher phosphorylation levels in stimulated cells
compared with unstimulated cells (P < 0.05). Values represent
mean ± SE (n = 4)
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Thr-210 phosphorylation, we assessed the effects of mutant
T210A Plk1 (alanine substitution at Thr-210) on MEK1/2
and ERK1/2 in smooth muscle cells. Immunoblot analysis
verified the expression of wild type (WT) or T210A Plk1 in
smooth muscle cells (Fig. 6a). In cells expressing WT Plk1,
PDGF stimulation induced the phosphorylation of MEK1/
2 and ERK1/2. In contrast, the PDGF-induced phosphoryl-
ation of MEK1/2 and ERK1/2 was reduced in cells express-
ing T210A Plk1 (Fig. 6b and c).
Furthermore, we also evaluated the effects of T210A
Plk1 on cell proliferation. In cells expressing WT Plk1,
PDGF treatment induced cell proliferation. However, the
expression of T210A Plk1 attenuated the PDGF-induced
cell proliferation (Fig. 6d).
Discussion
The protein kinase Plk1 has been implicated in various
cellular functions including mitosis and cytokinesis [2, 5].
Fig. 2 Knockdown (KD) of Plk1 attenuates the PDGF-induced phosphorylation of MEK1/2 and ERK1/2, but not Raf-1 phosphorylation.
a Representative immunoblots illustrating the effects of Plk1shRNA on Plk1 expression. Blots of HASM cells infected with lentiviruses
encoding control shRNA or Plk1 shRNA were probed with antibodies against Plk1 and GAPDH. Duplicated samples of each treatment are
shown. Ratios of Plk1/GAPDH protein in cells producing Plk1 shRNA were normalized to ratios obtained from cells producing control
shRNA. Values are mean ± SE (n = 4). *Significantly lower Plk1/GAPDH ratios in cells producing Plk1 shRNA compared with cells producing
control shRNA (P < 0.05). b Cells expressing control shRNA or Plk1 shRNA were treated with 20 ng/ml PDGF for 10 min, or they were not
stimulated. Protein phosphorylation was then evaluated by immunoblotting. MEK1/2 phosphorylation induced by PDGF was significantly
reduced in Plk1KD cells compared to cells treated with control shRNA (*P < 0.05). NS, basal MEK1/2 phosphorylation in Plk1 KD was not
significantly different from cells expressing control shRNA (P > 0.05). Values are mean ± SE (n = 8). c PDGF-induced ERK1/2 phosphorylation was
significantly reduced in Plk1 KD cells (*P < 0.05, n = 7). NS, basal ERK1/2 phosphorylation in Plk1 KD was not significantly different from cells
expressing control shRNA (P > 0.05). d PDGF-stimulated Raf-1 phosphorylation at Ser-338 was comparable in Plk1 KD cells and cells expressing
control shRNA. NS, Raf-1 phosphorylation in Plk1 KD was not significantly different from cells expressing control shRNA (P > 0.05, n = 8). Protein
phosphorylation under various treatments was normalized to the levels in unstimulated cells expressing control shRNA
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The physiological properties of Plk1 in the early stage
of the growth factor response have not been investi-
gated. In the present study, Plk1 underwent phosphor-
ylation at Thr-210 in quiescent smooth muscle cells
within minutes of PDGF stimulation. Structural ana-
lysis reveals that Plk1 is composed of a common N-
terminal catalytic domain and a C-terminal regulatory
domain with highly-conserved sequences named polo-
box domain (PBD), and an interdomain linker [7].
PBD is involved in an autoregulatory mechanism and
spatial localization [2, 7]. When inactive, PBD binds to
the catalytic domain, which inhibits the access of sub-
strates to the catalytic domain. Plk1 phosphorylation
at Thr-210 may induce the dissociation of PBD from
the catalytic domain, increasing kinase activity [2, 6, 7,
24]. Thus, the stimulation with the growth factor is
able to activate Plk1 in smooth muscle cells.
The activation of the MAPK pathway is a key event
in the early phase of cellular responses to growth fac-
tor stimulation. Our recent studies showed that the
MAPK pathway in airway smooth muscle is regulated
by Raf-1 [8], which is a known target of Ras [10, 11].
Thus, it is likely that the MAPK cascade is mediated
by the Ras-Raf pathway in smooth muscle. Although
the role of Plk1 in cell division/proliferation is well
recognized, the studies on Plk1 are largely focused on
the stages of mitosis and cytokinesis [2, 4, 5]. In this
report, stimulation with PDGF also induced the phos-
phorylation of MEK1/2 and ERK1/2, which is consist-
ent with previous results [8, 9, 25]. Furthermore, Plk1
activation preceded MEK/ERK activation in smooth
muscle cells upon PDGF stimulation. More import-
antly, Plk1 KD attenuated the PDGF-induced phos-
phorylation of MEK1/2 and ERK1/2. To the best of
our knowledge, this is the first evidence to suggest
that Plk1 is necessary for the activation of the MAPK
pathway in smooth muscle cells upon growth factor
stimulation.
Fig. 3 Plk1 catalyzes MEK phosphorylation in vitro. Purified active
Plk1 (40 ng) and 2 μg purified unactive MEK1 were placed in kinase
buffer. MEK phosphorylation was determined by immunoblot
analysis 30 min after the initiation of the reaction. a Representative
immunoblots illustrates Plk1-mediated MEK phosphorylation. b MEK
phosphorylation catalyzed by Plk1 was normalized to the level of
MEK phosphorylation in the absence of Plk1 (n = 4, *P < 0.05)
Fig. 4 Effects of Plk1 KD on smooth muscle cell proliferation. a
Smooth muscle cells expressing control shRNA or Plk1 shRNA were
treated with 20 ng/ml PDGF for 24–72 h. The numbers of viable
cells were then determined. Plk1 KD inhibits smooth muscle cell
proliferation. Data are mean ± SE (n = 4, * P < 0.05, **P < 0.01). b
Smooth muscle cells expressing control shRNA or Plk1 shRNA were
treated with or without 20 ng/ml PDGF for 24 h. DNA synthesis in
these cells was evaluated using the BrdU incorporation assay.
Newly-synthesized DNA was reduced in Plk1 KD cells. Data are
mean ± SE (n = 6, ** P < 0.01)
Fig. 5 AKT phosphorylation stimulated by PDGF is not reduced in Plk1
KD smooth muscle cells. Stable Plk1 KD cells and cells expressing control
shRNA were treated with 20 ng/ml PDGF for 10 min, or left untreated. a
Representative immunoblots illustrating the effects of Plk1 KD on AKT
phosphorylation. b Basal and the PDGF-induced AKT phosphorylation
(Ser-473) is similar in Plk1 KD cells and cells producing control shRNA
(P> 0.05). Stimulated AKT phosphorylation was normalized to the basal
level of cells expressing control shRNA. Values are mean ± SE (n= 4)
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In response to activation with growth factors, ERK1/
2 gets phosphorylated at Thr-202/Tyr-204, which is
catalyzed by the dual-specificity protein kinase MEK1/
2 [8, 10]. Since Plk1 is a serine/threonine protein kin-
ase [2, 5], it is unlikely that Plk1 catalyzes ERK1/2 dir-
ectly. Previous studies by others suggest that MEK1/2 is
phosphorylated at Ser-218/Ser-222 and activated by Raf
kinase during activation with growth factors [10, 11].
Moreover, in response to cell adhesion to fibronectin,
p21-activated kinase mediates MEK1/2 phosphorylation at
Ser-298, which subsequently promotes phosphorylation of
Ser-218/Ser-222 and activates MEK1/2 [26]. In the present
study, Plk1 KD did not affect Raf-1 phosphorylation in
smooth muscle cells. Plk1 directly catalyzed MEK phos-
phorylation at Ser-218/Ser-222 as evidenced by the in
vitro kinase assay. Thus, Plk1 may regulate the ERK1/2
Fig. 6 Expression of mutant T210A Plk1 inhibits the PDGF-induced phosphorylation of MEK1/2 and ERK1/2, and cell proliferation. a Smooth
muscle cells were transfected with plasmids encoding Flag-wild type (WT) or T210A Plk1. Blots of cell extracts were detected with antibodies
against Flag and GAPDH. Duplicated samples of each treatment are shown. Ratios of Plk1/GAPDH protein in cells transfected with plasmids were
normalized to untransfected cells. Values are mean ± SE (n = 4, *P < 0.01 vs. untransfected cells). b and c Cells expressing WT or T210A Plk1 were
treated with 20 ng/ml PDGF for 10 min, or they were not treated. Protein phosphorylation was then evaluated by immunoblotting. MEK1/2
phosphorylation (n = 5) and ERK1/2 phosphorylation (n = 4) induced by PDGF was significantly reduced in cells expressing T210A Plk1 compared
to cells expressing WT Plk1 (*P < 0.05). Protein phosphorylation under various treatments was normalized to the levels in unstimulated cells
expressing WT Plk1. Values are mean ± SE. NS, basal MEK1/2 or ERK1/2 phosphorylation in Plk1 KD was not significantly different from cells
expressing control shRNA (P > 0.05). d Smooth muscle cells expressing WT or T210A Plk1 were treated with 20 ng/ml PDGF for 24–72 h.
The numbers of viable cells were then determined. Data are mean ± SE (n = 4, *P < 0.05, **P < 0.01)
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activation by controlling MEK1/2 phosphorylation in
smooth muscle cells during stimulation with growth
factors.
As described earlier, the MAPK pathway is activated
within minutes in response to growth factor stimulation,
which phosphorylates and activates downstream targets
and promotes cell proliferation eventually (takes days)
[8–11]. In this report, Plk1 KD attenuated the PDGF-
induced phosphorylation of MEK1/2 and ERK1/2, DNA
synthesis and cell proliferation. The results support the
concept that Plk1-mediated MAPK activation (within mi-
nutes) ultimately affects smooth muscle cell proliferation.
AKT phosphorylation and activation may facilitate cell
survival in response to growth factor stimulation [9, 23].
Although Plk1 regulates the MAPK pathway, KD of Plk1
did not affect the PDGF-induced phosphorylation of
AKT. The results suggest that Plk1 differentially regu-
lates the activation of MEK1/2 and AKT in smooth
muscle cells. AKT phosphorylation may be regulated by
PI3 kinase, PTEN, the PIKK (PI3 kinase related kinase)
superfamily, mTORC2 (mammalian target of rapamycin
complex 2) and DNA-PK [23].
In this report, the expression of T210A Plk1 dimin-
ished the PDGF-induced phosphorylation of MEK1/2
and ERK1/2 as well as smooth muscle cell proliferation.
The results suggest that phosphorylation at Thr-210 is
required for the activation of MEK1/2 and ERK1/2, and
cell proliferation. Phosphorylation at this residue may
increase Plk1 activity, which in turn phosphorylates
MEK1/2 and activates the downstream events.
ERK1/2 has been shown to control transcription fac-
tors (Elk-1, Ets-2), ribosomal S6 kinase, MNK kinase,
and cPLA2, which regulate gene transcription, protein
translation and other processes that facilitate cell prolif-
eration [27, 28]. Future investigations are required to
assess whether these molecules are involved in the Plk1/
MAPK-regulated proliferation in smooth muscle cells.
Moreover, asthmatic airway smooth muscle cells display
different proliferative properties compared to non-
asthmatic smooth muscle cells [1]. Since Plk1 regulates
non-asthmatic airway smooth muscle cell proliferation,
it would be interesting to understand whether the Plk1/
MAPK pathway is altered in asthmatic airway smooth
muscle cells in future studies.
How PDGF stimulation induces Plk1 phosphorylation
at Thr-210 upon growth factor stimulation is currently
unknown. Ste20-like kinase (SLK) is a serine/threonine
protein kinase that has been implicated in spindle
orientation and microtubule organization during mi-
tosis [29–31]. In vitro studies suggest that SLK may
catalyze Plk1 phosphorylation at Thr-210, which may
facilitate G2/M transition [29, 32]. In addition, the kin-
ase Aurora-A and its cofactor Bora are pivotal for Plk1
phosphorylation at Thr-210 during mitosis of human
osteosarcoma U2OS cells [4]. Furthermore, phos-
phatidylinositol 3-kinase (PI3K) has been implicated
in Plk1 activation during mitotic phase of Hela cells
[33]. Future studies are needed to evaluate whether
SLK, Aurora-A/Bora and PI3K are upstream regulator
of Plk1 in smooth muscle cells in response to growth
factor stimulation.
Summary
Plk1 is a serine/threonine protein kinase that has been
implicated in mitosis and cytokinesis. Our present study
unveils a new and novel role that Plk1 plays in the regu-
lation of smooth muscle cell proliferation. In response
to activation of growth factors, Plk1 gets phosphorylated
at Thr-210 and activated. Activated Plk1 may promote
the phosphorylation and activation of MEK1/2, which
subsequently activates ERK1/2 and smooth muscle cell
proliferation. Thus, we propose that Plk1 controls cell
proliferation at multiple cellular stages including the ac-
tivation of MEK1/2, mitosis and cytokinesis.
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